Ladislau et al. demonstrated in 2018 that type I IFN pathway activation in vitro reproduces the main dermatomyositis pathological findings including muscle atrophy and vasculopathy, and the pathogenic effects in vitro were abolished by a Janus kinase (JAK) inhibitor ruxolitinib that targets the IFN pathway [25]. Here, IFNA1 is linked to vascular disorder.